Immunovant Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $-1.5M | — |
| FY2019 | — | $7.3M | $7.0M |
| FY2020 | — | $94.1M | $100.6M |
| FY2021 | — | $391.5M | $400.1M |
| FY2022 | — | $469.8M | $493.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $-1.5M | — |
| FY2019 | — | $7.3M | $7.0M |
| FY2020 | — | $94.1M | $100.6M |
| FY2021 | — | $391.5M | $400.1M |
| FY2022 | — | $469.8M | $493.8M |